drugset / Trial / NCT07642843
CM336 for Active Sjogren's Syndrome Study
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CM336 in adult participants with active primary Sjogren's Syndrome.
Timeline
- Start
- 2026-06
- Primary completion
- 2028-04
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM336 | Monoclonal antibody | — | Subcutaneous |